等待開盤 08-25 09:00:00
+0.002
+1.35%
Prime Medicine reported positive clinical data from its Phase 1/2 trial in Chronic Granulomatous Disease (CGD), demonstrating early efficacy and safety of Prime Editing. The company secured $144.2 million from a follow-on offering and up to $24 million from the Cystic Fibrosis Foundation to advance its pipeline. Allan Reine, M.D., was appointed CEO, leading a strategic restructuring to enhance operational efficiency. The company expects its cash ...
08-07 12:00
Prime Medicine (NASDAQ: PRME) announced the pricing of a public offering of 38 million shares at $3.30 per share, raising approximately $125.4 million before expenses. The underwriters have a 30-day option to purchase up to an additional 5.7 million shares. Proceeds will support the company’s gene editing therapies, utilizing its Prime Editing platform to develop one-time curative treatments for genetic diseases.
07-31 01:33
证券之星消息,截至2025年7月25日收盘,懒猪科技(08379.HK)报收于0.11港元,下跌0.87%,成交量192.0万股,成交额21.81万港元。
07-25 18:11
证券之星消息,截至2025年7月7日收盘,懒猪科技(08379.HK)报收于0.12港元,上涨2.59%,成交量71.0万股,成交额8.47万港元。
07-07 18:04
懒猪科技(08379.HK)发布公告,集团预期于截至2025年3月31日止年度将取得净溢利约160万港元,而2024年同期则取得净亏损约1560万港元。
06-27 17:50
Prime Medicine, a biotechnology company developing one-time curative genetic therapies, announced that its management will participate in two upcoming conferences: Jefferies Global Healthcare Conference on June 5, 2025, and Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. Live audio webcasts will be available on the company's website, www.primemedicine.com, with replays for 90 days. The company focuses on advancing its Prim...
05-29 12:00
证券之星消息,截至2025年5月27日收盘,懒猪科技(08379.HK)报收于0.12港元,下跌7.87%,换手率0.05%,成交量36.0万股,成交额4.23万港元。
05-27 18:06